Old Web
English
Sign In
Acemap
>
Paper
>
Evidence“The Classic”Review《肺がん》肺がん分子標的薬のあり方を決定づけた「EGFR変異」―Gefitinib or Carboplatin‐Paclitaxel in Pulmonary Adenocarcinoma
Evidence“The Classic”Review《肺がん》肺がん分子標的薬のあり方を決定づけた「EGFR変異」―Gefitinib or Carboplatin‐Paclitaxel in Pulmonary Adenocarcinoma
2016
tamura yousuke
Keywords:
Carboplatin/paclitaxel
Pulmonary adenocarcinoma
Gefitinib
Cancer research
Medicine
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]